Comparative study of hirustasin superfamily gene expression in two medicinal leeches
Basic science / genomics published in Genes (2025)
Abstract
BACKGROUND/OBJECTIVES: Leeches constitute a pharmacologically significant animal group in traditional medicine due to their antithrombotic peptides, which include numerous members of the hirustasin gene superfamily. However, a comparative expression profile of this pharmaceutically important family across different leech species is lacking. METHODS: This study conducted a comparative transcriptomic analysis of hirustasin gene superfamily expression in the hematophagous leech Hirudinaria manillensis and the non-hematophagous leech Whitmania pigra. RESULTS: The total expression of the hirustasin gene superfamily, quantified as transcripts per million (TPM), showed no significant difference (p = 0.237) between H. manillensis (11,802.60 ± 1596.59) and W. pigra (8623.12 ± 965.96). However, both species exhibited pronounced intergenic expression heterogeneity. Five dominantly expressed genes (TPM > 1000) in H. manillensis and three in W. pigra were identified, collectively comprising 81% and 62% of the total hirustasin gene superfamily expression per species, respectively. Critically, the dominantly expressed genes exhibited no phylogenetic correspondence between species. Integrating expression profiles with phylogenetic reconstruction identified five high-potential candidate genes: poecistasin_Hman2, hirustasin_like_Hman01, hirustasin_like_Hman11, guamerin_Wpig, and bdellastasin_Wpig. Population-level analysis revealed marked population-specific expression patterns in H. manillensis, contrasting with minimal inter-population divergence in W. pigra. Nevertheless, geographically distinct populations of both species showed significant variation in the expression of their respective dominantly expressed genes. CONCLUSIONS: These findings provide a set of high-priority candidate genes and insights into their expression characteristics, serving as a starting point for subsequent functional validation and, when integrated with other screening methods, for future antithrombotic drug discovery.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Comparative gene-expression study of hirustasin superfamily in two medicinal-leech species characterizing tissue-specific bioactive-compound expression patterns.
Por qué esto importa para la hirudoterapia
Este estudio transcriptómico comparativo analizó el perfil de expresión de la superfamilia de genes de péptidos antitrombóticos de la hirustasina en dos sanguijuelas, la hematófaga Hirudinaria manillensis y la no hematófaga Whitmania pigra, sin encontrar diferencias significativas en la expresión total de la superfamilia (p = 0.237), pero sí una marcada heterogeneidad entre genes y a nivel poblacional, y postulando cinco genes candidatos de alto potencial (incluidos poecistasin_Hman2 y bdellastasin_Wpig) para trabajos futuros. Para la hirudoterapia, fortalece el eje científico de la narrativa del descubrimiento de fármacos a partir del secretoma de las sanguijuelas: el valor antitrombótico de las sanguijuelas reside en familias de péptidos definidas que pueden ser mapeadas, priorizadas y, eventualmente, validadas como candidatos farmacológicos. Como análisis genómico/de expresión preclínico, únicamente identifica candidatos y no realiza ensayos funcionales, en animales o clínicos; los propios autores enmarcan los hallazgos como un punto de partida para la validación funcional posterior y el futuro descubrimiento de fármacos antitrombóticos, no como evidencia de actividad clínica.
Citación
Comparative study of hirustasin superfamily gene expression in two medicinal leeches.
Sun et al. · Genes, 2025
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026